

CURRENT REPORT 2/2024

January 17, 2023

Take-up of series K subscription warrants by the European Investment Bank

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow (the „Company”), with reference to current report no. 14/2022 of 17 August 2022, no. 19/2023 of 5 May 2023 and no. 33/2023 of 19 June 2023, hereby informs that on January 17, 2024 the Company entered into an agreement with the European Investment Bank with its seat in Luxembourg (“EIB”) for the subscription of series K subscription warrants (“Warrants”), under which the EIB subscribed for 592,825 (five hundred and ninety-two thousand eight hundred and twenty-five) Warrants, each of which entitles to subscribe for one series K share of the Company. The Warrants were taken up by the EIB free of charge.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Art. 17 (1) MAR - inside information

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board